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It is our hope that this document will serve several useful
purposes. Our primary goal is to improve patient care. We
hope to accomplish this, in the short term, by helping
clinicians know and better understand the evidence (or lack
of evidence) that determines current practice. By providing
comprehensive evidence-based recommendations, this guide-
line will also help define areas where evidence is lacking and
research is needed. Helping to define a research agenda is an
often neglected, but very important, function of clinical
practice guideline development.
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system to rate the
quality of evidence and the strength of recommendations.
In all, there were 12 (17.1%) recommendations in this
guideline for which the overall quality of evidence was
graded ‘A,’ whereas 36 (51.4%) were graded ‘B,’ 17 (24.3%)
were graded ‘C,’ and 5 (7.1%) were graded ‘D.’ Although
there are reasons other than quality of evidence to make
a grade 1 or 2 recommendation, in general, there is a
correlation between the quality of overall evidence and the
strength of the recommendation. Thus, there were 43
(62.3%) recommendations graded ‘1’ and 26 (37.7%) graded
‘2.’ There were 9 (13.0%) recommendations graded ‘1A,’ 23
(33.3%) were ‘1B,’ 10 (14.5%) were ‘1C,’ and 1 (1.4%) was
‘1D.’ There were 2 (2.9%) recommendations graded ‘2A,’
13 (18.8%) were ‘2B,’ 7 (10.1%) were ‘2C,’ and 4 (5.8%)
were ‘2D.’ There were 41 (37.3%) statements that were not
graded.
Some argue that recommendations should not be made
when evidence is weak. However, clinicians still need to make
decisions in their daily practice, and they often ask, ‘‘What do
the experts do in this setting?’’ We opted to give guidance,
rather than remain silent. These recommendations are often
rated with a low strength of recommendation and a low
quality of evidence, or were not graded. It is important for
the users of this guideline to be cognizant of this (see Notice).
In every case these recommendations are meant to be a place
for clinicians to start, not stop, their inquiries into specific
management questions pertinent to the patients they see in
daily practice.
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